The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Fullerene-based antioxidants and neurodegenerative disorders.
Abstract
Water-soluble derivatives of buckminsterfullerene (C(60)) derivatives are a unique class of compounds with potent antioxidant properties. Studies on one class of these compounds, the malonic acid C(60) derivatives (carboxyfullerenes), indicated that they are capable of eliminating both superoxide anion and H(2)O(2), and were effective inhibitors of lipid peroxidation, as well. Carboxyfullerenes demonstrated robust neuroprotection against excitotoxic, apoptotic and metabolic insults in cortical cell cultures. They were also capable of rescuing mesencephalic dopaminergic neurons from both MPP(+) and 6-hydroxydopamine-induced degeneration. Although there is limited in vivo data on these compounds to date, we have previously reported that systemic administration of the C(3) carboxyfullerene isomer delayed motor deterioration and death in a mouse model of familial amyotrophic lateral sclerosis (FALS). Ongoing studies in other animal models of CNS disease states suggest that these novel antioxidants are potential neuroprotective agents for other neurodegenerative disorders, including Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neuroprotective compounds based on carbon-60 fullerene – the molecules having a 3-D pattern of evenly spaced carbon atoms, have been fabricated by the application of nanotechnological approach (Dugan et al., 2001).”
From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Dugan et al., 2001
In the citing paper
“Free radicals, such as superoxide, hydroxyl, peroxynitrite, and peroxide, cause deleterious alterations in cells including DNA fragmentation, peroxidation of cell membrane lipids, mitochondrial energy disturbances and alteration in functionality of transporter proteins”
From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Dugan et al., 2001
In the citing paper
“they are considered as the main culprit having the key role in pathology of neurodegenerative, ischemic, and traumatic CNS disorders (Mahadik and Mukherjee, 1996; Dugan et al., 2001).”
From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Dugan et al., 2001
Citations
Cites
Carboxyfullerenes as neuroprotective agents
Dugan, L. L., Turetsky, D. M., Du, C., Lobner, D., Wheeler, M. E., Almli, C. R., Shen, C. K.-F., Luh, T., Choi, D. W., & Lin, T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9434 · Cited by 747
Self-citationDistinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons
Lotharius, J., Dugan, L. L., & O’Malley, K. L. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-04-01284.1999 · Cited by 403
Self-citationDugan, L. L., Gabrielsen, J. K., Yu, S. P., Lin, T., & Choi, D. W. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0013 · Cited by 384
Self-citationCarboxyfullerene Prevents Iron‐Induced Oxidative Stress in Rat Brain
Lin, A. M.-Y., Chyi, B. Y., Wang, S. D., Yu, H., Kanakamma, P. P., Luh, T., Chou, C., & Ho, L. T. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721634.x · Cited by 136
C 3 ‐Fullero‐ tris ‐Methanodicarboxylic Acid Protects Cerebellar Granule Cells from Apoptosis
Bisaglia, M., Natalini, B., Pellicciari, R., Straface, E., Malorni, W., Monti, D., Franceschi, D., & Schettini, G. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.741197.x · Cited by 94
Rapid microplate assay for superoxide scavenging efficiency
Quick, K. L., Hardt, J. I., & Dugan, L. L. (2000) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(00)00179-5 · Cited by 90
Self-citationHuang, Y., Shen, C. K.-F., Luh, T., Yang, H. C., Hwang, K. C., & Chou, C. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2540038.x · Cited by 86
Inhibition of Nitric Oxide Synthase Isoforms by Tris-Malonyl-C60-Fullerene Adducts
Wolff, D. J., Papoiu, A. D. P., Mialkowski, K., Richardson, C. F., Schuster, D. I., & Wilson, S. R. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1843 · Cited by 59
Straface, E., Natalini, B., Monti, D., Franceschi, C., Schettini, G., Bisaglia, M., Fumelli, C., Pincelli, C., Pellicciari, R., & Malorni, W. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00812-1 · Cited by 52
Cited by
Sorted by citations
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes
Wei, H., & Wang, E. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35486e · Cited by 3,779
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
Wu, J., Wang, X., Wang, Q., Lou, Z., Li, S., Zhu, Y., Qin, L., & Wei, H. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00457a · Cited by 4,136
Georgakilas, V., Perman, J. A., Tucek, J., & Zboril, R. (2015) · Chemical Reviews · doi:10.1021/cr500304f · Cited by 2,147
Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Structure and activity of nanozymes: Inspirations for de novo design of nanozymes
Wang, Z., Zhang, R., Yan, X., & Fan, K. (2020) · Materials Today · doi:10.1016/j.mattod.2020.08.020 · Cited by 900
Metadata
- Authors
- Dugan, L. L., Lovett, E. G., Quick, K. L., Lotharius, J., Lin, T. T., & O'Malley, K. L.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Dugan, L.L.
- ORCID
- Dugan, L.L.
- Venue
- Parkinsonism & Related Disorders
- Publisher
- Elsevier BV
- Published
- 2001-07
- Volume
- 7
- Issue
- 3
- Pages
- 243-246
- ISSN
- 1353-8020 (ISSN-L)
- OpenAlex
- W2126036130
- Cited by
- 338
- References
- 9
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 14 · 2020: 20 · 2019: 14 · 2018: 13 · 2017: 9 · 2016: 10 · 2015: 14 · 2014: 15 · 2013: 12 · 2012: 22
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Parkinsonism & Related Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Fullerene Chemistry and Applications
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
